Immunology / Virology & Vaccines

Vaccine
#Covid-19 #Immunology / Virology & Vaccines #University of Cambridge

‘Universal’ vaccine could protect from several viruses at once 

A novel ‘universal’ vaccine has been engineered to provide protection from thousands of variants in one single dose.  Results from a first-in-human clinical trial, published in the Journal of Infection, show the vaccine protected participants from multiple Sarbeco coronaviruses, a large group of viruses including SARS-CoV-2, as… Read More

#News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Eli Lilly #Immunology / Virology & Vaccines #Mergers and acquisitions

Lilly expansion aims to “prevent disease at its source”

Lilly has reached an acquisition agreement with LimmaTech Biologics AG, a Swiss clinical-stage biotech company, for up to $780 million.  The buy-out was part of a spending spree by Lilly on company pipelines that address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens… Read More

#Business & Investment #Editor's Choice #News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Vaccine discovery
#Ebola virus #Immunology / Virology & Vaccines #Outbreak #University of Oxford

UK group steps up Ebolavirus vaccine development in response to outbreak

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) has reported that it is working urgently with the Clinical BioManufacturing Facility and the Serum Institute of India (SIIPL) to rapidly produce and scale doses of its ChAdOx-based monovalent… Read More

#News #Trending News

Baby on a respirator - RSV
#Clinical trial #Immunology / Virology & Vaccines #Respiratory syncytial virus

International study will investigate RSV prevention in infants

A new international clinical trial has been launched to compare existing prevention options to protect babies from respiratory syncytial virus (RSV).  The PIPELINE-RSV trial, sponsored by Penta, will evaluate two licensed RSV prevention tools. The RSV vaccine which is routinely offered to all pregnant individuals in the… Read More

#News

mRNA
#CEPI #Immunology / Virology & Vaccines #Influenza #Moderna #mRNA #Pandemic prevention #Pandemic response

$54.3m CEPI investment boosts Moderna’s H5 influenza vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.   The organisation says the funding marks a significant step… Read More

#Business & Investment #News

Nasal spray
#Cancer treatment #Cervical cancer #HPV #Immunology / Virology & Vaccines #Oncology

Scientists create nasal vaccine for treating cervical cancer

Researchers at Chiba University in Japan have developed a new nasal therapeutic vaccine as a non-invasive treatment option for cervical cancer.   Cervical cancer is primarily caused by the human papillomavirus (HPV), but there are no approved therapeutic medicines to treat existing infections or HPV-associated cancers. … Read More

#Cancer Research #Editor's Choice #News

#Biopharma #Business #Duchenne muscular dystrophy #Immunology / Virology & Vaccines #Mitochondria #Obesity

DDW Highlights: 11 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s leading story came from a positive development in biopharma, with top companies… Read More

#Podcasts

#Biopharma #Business #Duchenne muscular dystrophy #Immunology / Virology & Vaccines #Mitochondria #Obesity

This week in Drug Discovery (3 – 7 November) 

News round-up for 3 – 7 November by Bruno Quinney, Content Team at DDW.    This week’s leading story is a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a… Read More

#News

Covid-19 vaccine
#Covid-19 #DNA technology #Drug discovery #Immunology / Virology & Vaccines #Infectious diseases

The potential of DNA platforms for infectious disease vaccines 

Stacy R. Lindborg, President and Chief Executive Officer of IMUNON, discusses why research is needed to inform better strategies for infectious diseases such as Covid-19 and a new, multivalent non-viral DNA approach to vaccine development that has the potential to address continued unmet needs in the field. … Read More

#Exclusive Content

Vaccine
#Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA-based vaccines

The expanding market of vaccines  

By Stephen Adams, Associate Director, Optimum Strategic Communications  To say that vaccines and vaccine makers have been on a popularity rollercoaster in recent years is an understatement. Five years ago, with the world’s biotechs and pharma firms engaged in a high-stakes race to develop the first… Read More

#Exclusive Content

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Mergers and acquisitions #Respiratory #Sanofi #Vaccines #Vicebio

Harnessing molecular clamp technology for respiratory vaccines

Sanofi explores the acquisition of Vicebio and its Molecular Clamp technology, highlighting how it strengthens the company’s respiratory vaccine portfolio with next-generation combination candidates. Q: Sanofi has described the acquisition of Vicebio as a step toward next-generation combination vaccines. What gaps or opportunities does this address in your… Read More

#Exclusive Content

Vaccine
#Clinical trials #Drug discovery #Immunology / Virology & Vaccines #Vaccines

Human challenge trial for pneumococcal vaccine launches in Malawi  

The first clinical trials for a new vaccine targeting pneumococcal disease in people in Malawi have been launched.  The human challenge trial will enrol 400 people in Malawi making it the biggest trial the country has seen to date.   The launch of the trial comes… Read More

#News

#Clinical trials #Drug discovery #Funding #Immunology / Virology & Vaccines #Obesity

This week in drug discovery 1-5 September

News round-up for 1-5 September by DDW Editor Reece Armstrong. There have been a number of stories this week promoting promising science in the areas of obesity and cardiology, along with a partnership to advance vaccine science. The top stories Research programme represents a “new frontier in vaccine… Read More

#News

#Immunology / Virology & Vaccines #Moderna #mRNA-based vaccines #Streptococcus #University of Queensland

Researchers step closer to a universal Strep-A mRNA vaccine

A team of microbiologists and immunologists has completed the first steps towards developing a universal vaccine against Group A Streptococcus (Strep-A).  The University of Queensland-led research in partnership with Moderna and published in Nature Communications has shown Strep-A can be successfully targeted using… Read More

#Editor's Choice #News